Proxygen’s second lead candidate, CDK12, is a brain-penetrant glue degrader program designed to inactivate the transcriptional kinase CDK12, a target implicated in aggressive HER2-driven cancers and ...

O'Henry's Coffee in Hoover received the lowest health inspection score in Jefferson County for the week of April 20-24 with ...

According to the Department of Justice (DOJ), on April 14, a federal judge in the U.S. District Court in Seattle sentenced ...

If you find yourself working from home more often than not these days, you might be thinking about all the ways you can upgrade your home office. But as you browse through fancy desks and ergonomic ...

SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rationally designed molecular glue ...